The value of serum E-cadherin and HMGB1 in ovarian cancer and its relationship with chemotherapy efficacy / 国际检验医学杂志

ABSTRACT

Objective To investigate the value of E-cadherin and HMGB1 in ovarian cancer and its relation-ship with the curative effect of chemotherapy.Methods The levels of E-cadherin and HMGB1 of 80 cases of newly diagnosed ovarian cancer patients before and after NAC chemotherapy and 60 cases of healthy controls were measured from October 2012 to October 2014.The patients were followed up after chemotherapy 24 ~36 months.The relationship between serum E-cadherin and HMGB1 and the long-term efficacy of ovarian cancer was analyzed.Results The levels of serum E-cadherin and HMGB1 in ovarian cancer before chemo-therapy were significantly higher than those in ovarian benign tumor and control group(P<0.05).The levels of serum E-cadherin and HMGB1 before chemotherapy were significantly lower than those before chemothera-py.The levels of serum E-cadherin and HMGB1 in CR+PR group were lower than those before chemotherapy (P<0.05),and the levels of E-cadherin and HMGB1 in SD+PD group were significantly higher than those in control group and CR+PR group(P<0.05).The level of E-cadherin and HMGB1 were correlated with clini-cal stage,tumor size and lymph node metastasis(P<0.05).The Cox risk model showed that E-cadherin>2.10 mg/L after chemotherapy,lymph node metastasis.After chemotherapy,HMGB1>115 μg/mL was an in-dependent risk factor for the progression-free survival of ovarian cancer(P<0.05).Conclusion The serum E-cadherin and HMGB1 levels before and after chemotherapy will help to evaluate the prognosis and recur-rence of ovarian cancer,and provide guidance for the next treatment.